Chinese AI company increases nearly 15% in partnership with Eli Lilly reaching $2.75 billion.

As of the time of writing, Yingzi Intelligent has risen by 14.95%. In terms of news, Eli Lilly and Yingzi Intelligent have reached a $2.75 billion cooperation agreement. Eli Lilly will obtain exclusive sales rights for a GLP-1 hypoglycemic drug developed by Yingzi Intelligent's AI technology, with an initial payment of $115 million and a total amount of up to $2.75 billion.